SciClone Announces Enrollment Completion In Phase 2 Oral Mucositis Trial Of SCV-07

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that patient enrollment is complete ahead of schedule for its phase 2 trial of SCV-07 a small molecule synthetic peptide with immunomodulating properties for the treatment of severe oral mucositis (OM) in patients with head and neck cancer. Topline results of the oral mucositis trial are expected to be announced in the first half of 2010.

source : www.medicalnewstoday.com

Related News:

• Merz Pharma Announces Launch Of Denzapine As First Available Generic For Treatment-Resistant Schizophrenia
• Protalix Announces Presentation Of Phase III Taliglucerase Alfa Data At WORLD Lysosomal Disease Network
• Auxilium Announces U.S. Food And Drug Administration Approval For XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
• Life Spine(R) Announces FDA Clearance Of DYNA-LINK(R) Spinal System And PRESIDIO(TM) Spinal Plating System
• NaturalNews announces chemical-free Chia seeds at under $5 a pound
• YM BioSciences Announces FDA Clearance For Two Ongoing Phase II Nimotuzumab Trials Into USA
• Inspire Announces Results Of Phase 3 PROLACRIA™ Trial For Dry Eye
• Sangamo BioSciences Announces Presentation Of Preliminary Data From Phase 1 Safety Trial Of SB-728-T For HIV/AIDS
• NaturalNews announces the "Dumb and Dumber and Dumberer" awards for 2009
• Alimera Announces Positive Results From The Two Phase 3 FAME(TM) Trials Of Iluvien(R) In Patients With Diabetic Macular Edema

Details :
Submited at Tuesday, November 24th, 2009 at 7:00 am on ENT by hilman
Comment RSS 2.0 - leave a comment - trackback